

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	67	"4943590"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/06/15 14:45
L3	25	("4136193" "4650884").PN. OR ("4943590").URPN.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:27
L5	44	lyng.in.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:28
L6	285	mork.in.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:29
L7	7	l6 and serotonin	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:33
L8	0	"10516519"	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:38
L9	1825	sanchez.in.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 15:38
L10	74	l9 and (depression\$ or serotonin\$ or escitalopram)	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:54
L11	980	514/469.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:54
L12	21	l11 and escitalopram	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:55
L13	325	558/422.ccls.	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:55
L14	0	l13 and escitalopram	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:56
L15	13	l13 and serotonin	US-PGPUB; USPAT; USOCR	OR	ON	2005/06/15 16:56
S11	114	escitalopram	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/06/15 11:09

S12	1581	citalopram	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/06/15 14:45
S14	980	S12 and (\$depression\$ or \$menstrual\$ or \$attention\$)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/06/15 10:11

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptayscl617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 10 MAR 22 PATDPASPC - New patent database available
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new
fields
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced
NEWS 14 APR 18 New CAS Information Use Policies available online
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),
based on application date in CA/CAPLUS and USPATFULL/USPAT2
may be affected by a change in filing date for U.S.
applications.
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for
U.S. patent records in CA/CAPLUS
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from
CHEMCATS
NEWS 19 JUN 06 STN Patent Forums to be held in June 2005
NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover!
(Version 8.0 for Windows) now available
NEWS 21 JUN 13 RUSSIAPAT: New full-text patent database on STN
NEWS 22 JUN 13 FRFULL enhanced with patent drawing images

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:55:50 ON 15 JUN 2005

=> FIL STNGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'STNGUIDE' ENTERED AT 12:55:59 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 10, 2005 (20050610/UP).

=> file registry
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.06	0.27

FILE 'REGISTRY' ENTERED AT 12:56:13 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2005 HIGHEST RN 852282-01-0
DICTIONARY FILE UPDATES: 14 JUN 2005 HIGHEST RN 852282-01-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer.
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\Program Files\Stnexp\Queries\escitalopram.str



```

chain nodes :
11 12 13 14 15 16 17 18 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
41 42
ring nodes :
1 2 3 4 5 6 7 8 9 10 19 20 21 22 23
chain bonds :
1-31 2-30 3-18 4-32 7-33 7-34 9-10 9-11 11-12 11-35 11-36 12-13 12-37 12-38 13-14
13-39 13-40 14-15 14-41 14-42 15-16 15-17 19-27 20-26 21-24 22-29 23-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-19 10-23 19-20 20-21 21-22 22-23
exact/norm bonds :
8-9
exact bonds :
1-31 2-30 3-18 4-32 5-7 6-9 7-8 7-33 7-34 9-10 9-11 11-12 11-35 11-36 12-13
12-37 12-38 13-14 13-39 13-40 14-15 14-41 14-42 15-16 15-17 19-27 20-26 21-24
22-29 23-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-19 10-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 10 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS 42:CLASS

```

Stereo Bonds:

9-8 (Single Wedge).
11-9 (Single Hash).

Stereo Chiral Centers:

9 (Parity=Even)

Stereo RSS Sets:

Type=Absolute (Default). 1 Nodes= 9

L1 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 12:56:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full


FULL SEARCH INITIATED 12:57:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\escitalopram1.str



chain nodes :

11 12 13 14 15 16 17 23 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
41 42 43

ring nodes :

1 2 3 4 5 6 7 8 9 10 18 19 20 21 22

chain bonds :

1-30 2-29 3-42 4-31 7-32 7-33 9-10 9-11 11-12 11-34 11-35 12-13 12-36 12-37 13-14
13-38 13-39 14-15 14-40 14-41 15-16 15-17 18-26 19-25 20-23 21-28 22-27 42-43

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-18 10-22 18-19 19-20 20-21 21-22

exact/norm bonds :

8-9 42-43

exact bonds :

1-30 2-29 3-42 4-31 5-7 6-9 7-8 7-32 7-33 9-10 9-11 11-12 11-34 11-35 12-13
12-36 12-37 13-14 13-38 13-39 14-15 14-40 14-41 15-16 15-17 18-26 19-25 20-23
21-28 22-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-18 10-22 18-19 19-20 20-21 21-22

isolated ring systems :

containing 1.: 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Stereo Bonds:

9-8 (Single Wedge).
11-9 (Single Hash).

Stereo Chiral Centers:

9 (Parity=Even)

Stereo RSS Sets:

Type=Absolute (Default). 1 Nodes= 9

L4 STRUCTURE UPLOADED

=> s l4

SAMPLE SEARCH INITIATED 12:59:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> file caplus medline biosis
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	164.34	164.61

FILE 'CAPLUS' ENTERED AT 13:01:16 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:01:16 ON 15 JUN 2005

FILE 'BIOSIS' ENTERED AT 13:01:16 ON 15 JUN 2005
Copyright (c) 2005 The Thomson Corporation

=> s escitalopram
L6 327 ESCITALOPRAM

=> l6 and ?depression?
L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l6 and ?depression?
L7 171 L6 AND ?DEPRESSION?

=> dup rem
ENTER L# LIST OR (END):17
PROCESSING COMPLETED FOR L7
L8 117 DUP REM L7 (54 DUPLICATES REMOVED)

=> s l6 and ?menstrual?
L9 14 L6 AND ?MENSTRUAL?

=> dup rem
ENTER L# LIST OR (END):19
PROCESSING COMPLETED FOR L9
L10 14 DUP REM L9 (0 DUPLICATES REMOVED)

=> d ibib abs tot

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:232623 CAPLUS

DOCUMENT NUMBER: 142:291420

TITLE: The combination of a serotonin reuptake inhibitor and amoxapine for the treatment of depression and other affective disorders

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Willigers, Sandra Hogg; Arnt, Jorn

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023266	A1	20050317	WO 2004-DK580	20040901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: DK 2003-1269 A 20030904
US 2003-500792P P 20030904

AB The invention discloses the use of a combination of amoxapine and a serotonin reuptake inhibitor (e.g. **escitalopram**), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:232608 CAPLUS

DOCUMENT NUMBER: 142:291419

TITLE: The combination of a serotonin reuptake inhibitor and loxapine for the treatment of depression and other affective disorders

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Willigers, Sandra Hogg; Arnt, Jorn

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023243	A1	20050317	WO 2004-DK581	20040901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:

DK 2003-1270 A 20030904
US 2003-500809P P 20030904

AB The invention discloses the use of a combination of loxapine and a serotonin reuptake inhibitor, e.g. **escitalopram**, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:177917 CAPLUS

DOCUMENT NUMBER: 142:274044

TITLE: The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 (GlyT-1) inhibitor for the treatment of depression, anxiety, and other affective disorders

INVENTOR(S): Didriksen, Michael; Hogg Willigers, Sandra; Arnt, Jorn

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018676	A1	20050303	WO 2004-DK547	20040818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

DK 2003-1198 A 20030821
US 2003-496738P P 20030821

AB The invention discloses the use of a compound which is a serotonin reuptake inhibitor and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders, and other affective disorders. In particular the invention relates to treatment of depression, anxiety disorders, and other affective disorders, e.g. generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, **premenstrual** syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The invention also discloses a pharmaceutical composition comprising a serotonin reuptake inhibitor and a GlyT-1 inhibitor.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:29189 CAPLUS

DOCUMENT NUMBER: 142:127610

TITLE: The combination of a serotonin reuptake inhibitors and agomelatine for the treatment of depression and other affective disorders

INVENTOR(S): Willigers, Sandra

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002562	A1	20050113	WO 2004-DK464	20040629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

DK 2003-1031 A 20030704
US 2003-485479P P 20030707

AB The invention discloses the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:409239 CAPLUS

DOCUMENT NUMBER: 142:441921

TITLE: Method of treating **premenstrual** dysphoric disorder with **escitalopram**

INVENTOR(S): Sanchez, Connie

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101666	A1	20050512	US 2004-984536	20041108
WO 2005046673	A1	20050526	WO 2003-US35541	20031107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-518276P P 20031107

AB The invention relates to a method of treating the symptoms of **premenstrual** dysphoric disorder (PMDD) in a patient in need thereof by administration of an effective amount of **escitalopram** or a pharmaceutically acceptable salt thereof.

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:140794 CAPLUS

DOCUMENT NUMBER: 142:225811

TITLE: Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's **menstrual** cycle

INVENTOR(S): Boissonneault, Roger M.; Devries, Tina M.; Ellman, Herman; MacFarlane, Kathryn L.; Smith, Kelly F.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 762,263.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

CODEN: USXXCO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005038005	A1	20050217	US 2004-819764	20040407
PRIORITY APPLN. INFO.:			US 2003-639891	B2 20030812
			US 2004-762263	A2 20040123

AB The present invention is a method of non-continuous administration of a pharmaceutical to a female for a condition associated with the female's **menstrual** cycle, comprising ascertaining a number of days in the female's **menstrual** cycle, and then administering a daily first dosage, starting on the first or the second day of the **menstrual** cycle and continuing the daily administration for a first dosage period. Next administering a daily second dosage, starting on the day after the last daily first dosage was administered and continuing the daily administration of the second dosage for a second dosage period. Either the first dosage is a placebo and the second dosage is the pharmaceutical, or the first dosage is the pharmaceutical and the second dosage is a placebo. Both the first dosages and the second dosages being contained in a single package. A package contains placebos and a selective serotonin reuptake inhibitor such as fluoxetine.

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:59985 CAPLUS

DOCUMENT NUMBER: 142:141291

TITLE: Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

INVENTOR(S): Marek, Gerard J.; Giller, Earl L.; Ramey, Tanya S.; Gibbs, Megan A.; Wong, Erik H. F.; Marshall, Robert C.

PATENT ASSIGNEE(S): Pfizer, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 602,447.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005014848	A1	20050120	US 2004-769018	20040130
US 2002107249	A1	20020808	US 2002-55663	20020123
US 2004102440	A1	20040527	US 2003-602447	20030624
WO 2005023265	A1	20050317	WO 2004-IB2864	20040902
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

NL 1026989 A1 20050310 NL 2004-1026989 20040908

PRIORITY APPLN. INFO.:


US 2002-55663	A2 20020123
US 2002-392893P	P 20020701
US 2003-602447	A2 20030624
US 2003-501275P	P 20030909
US 2004-538898P	P 20040123
US 2004-540696P	P 20040130
US 1999-141968P	P 19990701
US 1999-144131P	P 19990716
US 1999-158256P	P 19991006
US 1999-170381P	P 19991213

US 2000-599213
US 2004-769018
US 2004-860721


A3 20000622
A 20040130
A 20040603

OTHER SOURCE(S):
GI


MARPAT 142:141291



I



II



III

AB This invention is directed to pharmaceutical compns. and methods for treating a disorder or condition selected from the group consisting of depression, anxiety disorders, phobias, avoidant personality disorder, eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, neg. symptoms of schizophrenia, cognitive dysfunction related to schizophrenia, **premenstrual** syndrome, stress-induced incontinence, headache, neuropathic pain, chronic pain, urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress, fibromyalgia, depression comorbid with fibromyalgia, obesity, migraine and a combination thereof in a mammal. The methods in one embodiment comprise administering to a mammal in need of treatment for the disorder or condition: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure (I), Structure (II), and Structure (III) as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compns. and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1156491 CAPLUS

DOCUMENT NUMBER: 142:69208

TITLE: Gaboxadol and serotonin reuptake inhibitors for the treatment of depression and other affective disorders

INVENTOR(S): Sanchez, Connie; Ebert, Bjarke

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112786	A2	20041229	WO 2004-DK459	20040625

WO 2004112786 A3 20050414

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

DK 2003-956 A 20030625
US 2003-483019P P 20030625
DK 2004-16 A 20040107
US 2004-535123P P 20040107

AB The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:550944 CAPLUS

DOCUMENT NUMBER: 141:106358

TITLE: Solvent salification method for the preparation of **escitalopram** hydrobromide

INVENTOR(S): Martel, Lawrence; Dancer, Robert; Petersen, Hans; Ellegaard, Peter

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056791	A1	20040708	WO 2003-DK902	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004167209	A1	20040826	US 2003-746913	20031223

PRIORITY APPLN. INFO.:

DK 2002-2005 A 20021223

AB **Escitalopram** (i.e., S-citalopram) in the form of its hydrobromide salt is prepared by the solvent salification of S-citalopram base with HBr and psychiatric uses (e.g., the treatment of depression) for S-citalopram hydrobromide are claimed, as are pharmaceutical dosage formulations containing it.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392439 CAPLUS

DOCUMENT NUMBER: 140:400095

TITLE: Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.

PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039320	A2	20040513	WO 2003-US33681	20031022
WO 2004039320	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004142904	A1	20040722	US 2003-691465	20031022
PRIORITY APPLN. INFO.:			US 2002-421640P	P 20021025
			US 2002-423062P	P 20021101
			US 2003-445142P	P 20030205

OTHER SOURCE(S): MARPAT 140:400095

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC₅₀ = 28.6 nM for norepinephrine, IC₅₀ = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC₅₀ = 10.3 nM for norepinephrine, IC₅₀ = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC₅₀ = 88.5 nM for norepinephrine, IC₅₀ = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally, the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220191 CAPLUS

DOCUMENT NUMBER: 140:247089

TITLE: Use of a SRI and vitamin B6 for the treatment of neurological and mental disorders

INVENTOR(S): Van Der Linden, Rene Frank; Coelingh Bennink, Herman Jan Tijmen

PATENT ASSIGNEE(S): Pantarhei Bioscience B.V., Neth.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022043	A1	20040318	WO 2003-NL622	20030905
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

EP 2002-78645

A 20020905

AB Method is disclosed for the treatment of neurol. and/or mental disorders that are associated with, or pathogenetically related to deficient serotonin neurotransmission. More particularly the invention relates to a method of treating depressive disorders, anxiety disorders, post-traumatic stress syndrome or **premenstrual** syndrome, said method comprising the administration of serotonin re-uptake inhibitor (SRI) in a daily amount of at least 0.4 mg, wherein a vitamin B6 component is co-administered in a daily amount of between 0.01 and 10 mmoles to improve the responder rate or to advance the onset of action of the treatment with SRI, and wherein the method does not include the application to the brain of an AC pulsed magnetic field of at least 7.5 picotesia flux d. for at least 15 min. The invention also encompasses pharmaceutical formulations containing SRI and vitamin B6 component and comprising a dosage unit that provides a sustained release of the vitamin B6 component.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:2708 CAPLUS

DOCUMENT NUMBER: 140:53450

TITLE: Serotonin reuptake inhibitor combination with a GABAB receptor antagonist for the treatment of depression and other disorders

INVENTOR(S): Mork, Arne; Cremers, Thomas Ivo Franciscus Hubert; Willigers, Sandra

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000326	A1	20031231	WO 2003-DK412	20030619
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

BR 2003011503 A 20050222 BR 2003-11503 20030619

PRIORITY APPLN. INFO.: DK 2002-943 A 20020620

US 2002-390851P P 20020620

WO 2003-DK412 W 20030619

AB The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, **premenstrual** syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:849423 CAPLUS

DOCUMENT NUMBER: 137:320331

TITLE: The use of enantiomerically pure **escitalopram** for the treatment of depression and other disorders

INVENTOR(S): Sanchez, Connie; Lyng Jensen, Jesper; Mork, Arne
 PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087566	A1	20021107	WO 2002-DK281	20020501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2445843	AA	20021107	CA 2002-2445843	20020501
EP 1385503	A1	20040204	EP 2002-724141	20020501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008283	A	20040309	BR 2002-8283	20020501
JP 2004527551	T2	20040909	JP 2002-584912	20020501
US 2004192764	A1	20040930	US 2003-644576	20030820
US 2004192765	A1	20040930	US 2003-644579	20030820
US 2004192766	A1	20040930	US 2003-644588	20030820
US 2004198810	A1	20041007	US 2003-644577	20030820
US 2004198811	A1	20041007	US 2003-644587	20030820
ZA 2003007102	A	20040913	ZA 2003-7102	20030911
NO 2003004538	A	20031009	NO 2003-4538	20031009
BG 108379	A	20041130	BG 2003-108379	20031124
US 2004198809	A1	20041007	US 2004-468685	20040608
PRIORITY APPLN. INFO.:			DK 2001-684	A 20010501
			WO 2002-DK281	W 20020501

AB The invention discloses the use of enantiomerically pure **escitalopram** and/or low-dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment-resistant" patients.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:434867 CAPLUS

DOCUMENT NUMBER: 135:29158

TITLE: The combination of a serotonin reuptake inhibitor and irindalone for the treatment of depression and other affective disorders

INVENTOR(S): Bogeso, Klaus Peter; Cremers, Thomas Ivo Franciscus Hubert

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041766	A1	20010614	WO 2000-DK667	20001204

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002103249 A1 20020801 US 2000-731411 20001206
TR 200201512 T2 20020923 TR 2002-200201512 20001206
EP 1396267 A2 20040310 EP 2003-27672 20001206
EP 1396267 A3 20040421

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

ZA 2002004391 A 20030901 ZA 2002-4391 20020531

PRIORITY APPLN. INFO.: US 1999-169245P P 19991206
EP 2000-981174 A3 20001206

AB The invention discloses the use of a combination of irindalone and a
serotonin reuptake inhibitor, or any other compound which causes an
elevation in the level of extracellular serotonin, for the treatment of
depression and other affective disorders.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:55:50 ON 15 JUN 2005)

FILE 'STNGUIDE' ENTERED AT 12:55:59 ON 15 JUN 2005

FILE 'REGISTRY' ENTERED AT 12:56:13 ON 15 JUN 2005

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 STRUCTURE UPLOADED
L5 0 S L4

FILE 'CAPLUS, MEDLINE, BIOSIS' ENTERED AT 13:01:16 ON 15 JUN 2005

L6 327 S ESCITALOPRAM
L7 171 S L6 AND ?DEPRESSION?
L8 117 DUP REM L7 (54 DUPLICATES REMOVED)
L9 14 S L6 AND ?MENSTRUAL?
L10 14 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l6 and ?attention(3w)deficit(3w)hyperactivity?

L11 11 L6 AND ?ATTENTION(3W) DEFICIT(3W) HYPERACTIVITY?

=> dup rem

ENTER L# LIST OR (END):111

PROCESSING COMPLETED FOR L11

L12 11 DUP REM L11 (0 DUPLICATES REMOVED)

=> d ibib abs tot

L12 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:232623 CAPLUS

DOCUMENT NUMBER: 142:291420

TITLE: The combination of a serotonin reuptake inhibitor and
amoxapine for the treatment of depression and other
affective disorders

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Willigers,
Sandra Hogg; Arnt, Jorn

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023266	A1	20050317	WO 2004-DK580	20040901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: DK 2003-1269 A 20030904
US 2003-500792P P 20030904

AB The invention discloses the use of a combination of amoxapine and a serotonin reuptake inhibitor (e.g. **escitalopram**), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:232608 CAPLUS

DOCUMENT NUMBER: 142:291419

TITLE: The combination of a serotonin reuptake inhibitor and loxapine for the treatment of depression and other affective disorders

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Willigers, Sandra Hogg; Arnt, Jorn

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023243	A1	20050317	WO 2004-DK581	20040901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: DK 2003-1270 A 20030904
US 2003-500809P P 20030904

AB The invention discloses the use of a combination of loxapine and a serotonin reuptake inhibitor, e.g. **escitalopram**, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:177917 CAPLUS

DOCUMENT NUMBER: 142:274044

TITLE: The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 (GlyT-1) inhibitor for the treatment of depression, anxiety, and other

INVENTOR(S): affective disorders
 Didriksen, Michael; Hogg Willigers, Sandra; Arnt, Jorn
 PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018676	A1	20050303	WO 2004-DK547	20040818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: DK 2003-1198 A 20030821
 US 2003-496738P P 20030821

AB The invention discloses the use of a compound which is a serotonin reuptake inhibitor and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders, and other affective disorders. In particular the invention relates to treatment of depression, anxiety disorders, and other affective disorders, e.g. generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, **attention deficit hyperactivity** disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The invention also discloses a pharmaceutical composition comprising a serotonin reuptake inhibitor and a GlyT-1 inhibitor.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:29189 CAPLUS

DOCUMENT NUMBER: 142:127610

TITLE: The combination of a serotonin reuptake inhibitors and agomelatine for the treatment of depression and other affective disorders

INVENTOR(S): Willigers, Sandra

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002562	A1	20050113	WO 2004-DK464	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:

DK 2003-1031 A 20030704
US 2003-485479P P 20030707

AB The invention discloses the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1156491 CAPLUS

DOCUMENT NUMBER: 142:69208

TITLE: Gaboxadol and serotonin reuptake inhibitors for the treatment of depression and other affective disorders

INVENTOR(S): Sanchez, Connie; Ebert, Bjarke

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112786	A2	20041229	WO 2004-DK459	20040625
WO 2004112786	A3	20050414		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

DK 2003-956 A 20030625
US 2003-483019P P 20030625
DK 2004-16 A 20040107
US 2004-535123P P 20040107

AB The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:550944 CAPLUS

DOCUMENT NUMBER: 141:106358

TITLE: Solvent salification method for the preparation of **escitalopram** hydrobromide

INVENTOR(S): Martel, Lawrence; Dancer, Robert; Petersen, Hans; Ellegaard, Peter

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056791	A1	20040708	WO 2003-DK902	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004167209 A1 20040826 US 2003-746913 20031223

PRIORITY APPLN. INFO.: DK 2002-2005 A 20021223

AB **Escitalopram** (i.e., S-citalopram) in the form of its hydrobromide salt is prepared by the solvent salification of S-citalopram base with HBr and psychiatric uses (e.g., the treatment of depression) for S-citalopram hydrobromide are claimed, as are pharmaceutical dosage formulations containing it.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392439 CAPLUS

DOCUMENT NUMBER: 140:400095

TITLE: Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.

PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039320	A2	20040513	WO 2003-US33681	20031022
WO 2004039320	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004142904 A1 20040722 US 2003-691465 20031022

PRIORITY APPLN. INFO.: US 2002-421640P P 20021025

US 2002-423062P P 20021101

US 2003-445142P P 20030205

OTHER SOURCE(S): MARPAT 140:400095

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC50 = 28.6 nM for norepinephrine, IC50 = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50 = 10.3 nM for norepinephrine, IC50 = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC50 = 88.5 nM for norepinephrine, IC50 = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally, the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

ACCESSION NUMBER: 2004:2708 CAPLUS
 DOCUMENT NUMBER: 140:53450
 TITLE: Serotonin reuptake inhibitor combination with a GABAB receptor antagonist for the treatment of depression and other disorders
 INVENTOR(S): Mork, Arne; Cremers, Thomas Ivo Franciscus Hubert; Willigers, Sandra
 PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000326	A1	20031231	WO 2003-DK412	20030619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2003011503	A	20050222	BR 2003-11503	20030619
PRIORITY APPLN. INFO.: DK 2002-943 A 20020620 US 2002-390851P P 20020620 WO 2003-DK412 W 20030619				

AB The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, **attention deficit hyperactivity** disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 11 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 ACCESSION NUMBER: 2004:214002 BIOSIS
 DOCUMENT NUMBER: PREV200400210848
 TITLE: Annual Update 2003: Drugs for Psychiatric Disorders and Substance Abuse.
 AUTHOR(S): Anonymous
 SOURCE: Drugs of the Future, (November 2003) Vol. 28, No. 11, pp. 1103-1144. print.
 ISSN: 0377-8282.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 ENTRY DATE: Entered STN: 14 Apr 2004
 Last Updated on STN: 14 Apr 2004

AB This month's Annual Update 2003, dedicated to Drugs for Psychiatric Disorders and Substance Abuse, is comprised of a compendium of 137 drugs for the treatment of anxiety disorders, depression, bipolar disorder, schizophrenia, autism, **attention deficit hyperactivity** disorder, sleep disorders, alcohol abuse and alcoholism, drug abuse and addiction, and smoking cessation. The table of drugs includes products which have been launched for the first time since 2002 and others that were previously marketed for another indication. Products featured in the monograph updates section include agomelatine, aripiprazole, blonanserin, duloxetine hydrochloride, **escitalopram**

oxalate, eszopiclone, gepirone hydrochloride, indiplon, INN-00835, lamotrigine, nalmefene, naltrexone hydrochloride, ocinaplon, olanzapine, pregabalin, quetiapine fumarate, TAK-375 and venlafaxine hydrochloride.

L12 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:849423 CAPLUS
DOCUMENT NUMBER: 137:320331
TITLE: The use of enantiomerically pure **escitalopram** for the treatment of depression and other disorders
INVENTOR(S): Sanchez, Connie; Lyng Jensen, Jesper; Mork, Arne
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087566	A1	20021107	WO 2002-DK281	20020501
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2445843	AA	20021107	CA 2002-2445843	20020501
EP 1385503	A1	20040204	EP 2002-724141	20020501
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008283	A	20040309	BR 2002-8283	20020501
JP 2004527551	T2	20040909	JP 2002-584912	20020501
US 2004192764	A1	20040930	US 2003-644576	20030820
US 2004192765	A1	20040930	US 2003-644579	20030820
US 2004192766	A1	20040930	US 2003-644588	20030820
US 2004198810	A1	20041007	US 2003-644577	20030820
US 2004198811	A1	20041007	US 2003-644587	20030820
ZA 2003007102	A	20040913	ZA 2003-7102	20030911
NO 2003004538	A	20031009	NO 2003-4538	20031009
BG 108379	A	20041130	BG 2003-108379	20031124
US 2004198809	A1	20041007	US 2004-468685	20040608
PRIORITY APPLN. INFO.:			DK 2001-684	A 20010501
			WO 2002-DK281	W 20020501

AB The invention discloses the use of enantiomerically pure **escitalopram** and/or low-dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, **attention deficit hyperactivity** disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment-resistant" patients.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:434867 CAPLUS
DOCUMENT NUMBER: 135:29158
TITLE: The combination of a serotonin reuptake inhibitor and irindalone for the treatment of depression and other affective disorders
INVENTOR(S): Bogeso, Klaus Peter; Cremers, Thomas Ivo Franciscus Hubert
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 29 pp.

DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 2 English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041766	A1	20010614	WO 2000-DK667	20001204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002103249	A1	20020801	US 2000-731411	20001206
TR 200201512	T2	20020923	TR 2002-200201512	20001206
EP 1396267	A2	20040310	EP 2003-27672	20001206
EP 1396267	A3	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2002004391	A	20030901	ZA 2002-4391	20020531
PRIORITY APPLN. INFO.: US 1999-169245P P 19991206				
EP 2000-981174 A3 20001206				

AB The invention discloses the use of a combination of irindalone and a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	89.01	253.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-17.52	-17.52

STN INTERNATIONAL LOGOFF AT 13:14:04 ON 15 JUN 2005